Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
The impact of bisphosphonate therapy on the survival time of patients undergoing radiotherapy for bone metastases.

Ortopedia, traumatologia, rehabilitacja

Brzozowska A, Mazurkiewicz M, Mazurkiewicz T, Grzybowska-Szatkowska L.
PMID: 18034010
Ortop Traumatol Rehabil. 2003 Apr 30;5(2):223-6.

Background. Bisphosphonates are form of medical therapy for bone metastases. Morbidity from bone metastases including hypercalcemia episodes, pain, pathological fractures and appearance of new metastases in skeletal system is decreased by bisphosphonate therapy. The aim of this article is...

Cite
Brzozowska A, Mazurkiewicz M, Mazurkiewicz T, et al. The impact of bisphosphonate therapy on the survival time of patients undergoing radiotherapy for bone metastases. Ortop Traumatol Rehabil. 2003;5(2):223-6
Brzozowska, A., Mazurkiewicz, M., Mazurkiewicz, T., & Grzybowska-Szatkowska, L. (2003). The impact of bisphosphonate therapy on the survival time of patients undergoing radiotherapy for bone metastases. Ortopedia, traumatologia, rehabilitacja, 5(2), 223-6.
Brzozowska, Anna, et al. "The impact of bisphosphonate therapy on the survival time of patients undergoing radiotherapy for bone metastases." Ortopedia, traumatologia, rehabilitacja vol. 5,2 (2003): 223-6.
Brzozowska A, Mazurkiewicz M, Mazurkiewicz T, Grzybowska-Szatkowska L. The impact of bisphosphonate therapy on the survival time of patients undergoing radiotherapy for bone metastases. Ortop Traumatol Rehabil. 2003 Apr 30;5(2):223-6. PMID: 18034010.
Copy Download .nbib Format: NLM
Treatment of hepatic metastases with computed tomography-guided interstitial brachytherapy.

Oncology letters

Kieszko D, Cisek P, Kordzińska-Cisek I, Grzybowska-Szatkowska L.
PMID: 29928323
Oncol Lett. 2018 Jun;15(6):8717-8722. doi: 10.3892/ol.2018.8415. Epub 2018 Apr 02.

The aim of the present study was to evaluate the efficacy, safety and tolerability of local treatment of liver metastases of various types of cancer using brachytherapy with computed tomography (CT) imaging. Retrospective analysis of 61 patients with unresectable...

Cite
Kieszko D, Cisek P, Kordzińska-Cisek I, et al. Treatment of hepatic metastases with computed tomography-guided interstitial brachytherapy. Oncol Lett. 2018;15(6):8717-8722doi: 10.3892/ol.2018.8415.
Kieszko, D., Cisek, P., Kordzińska-Cisek, I., & Grzybowska-Szatkowska, L. (2018). Treatment of hepatic metastases with computed tomography-guided interstitial brachytherapy. Oncology letters, 15(6), 8717-8722. https://doi.org/10.3892/ol.2018.8415
Kieszko, Dariusz, et al. "Treatment of hepatic metastases with computed tomography-guided interstitial brachytherapy." Oncology letters vol. 15,6 (2018): 8717-8722. doi: https://doi.org/10.3892/ol.2018.8415
Kieszko D, Cisek P, Kordzińska-Cisek I, Grzybowska-Szatkowska L. Treatment of hepatic metastases with computed tomography-guided interstitial brachytherapy. Oncol Lett. 2018 Jun;15(6):8717-8722. doi: 10.3892/ol.2018.8415. Epub 2018 Apr 02. PMID: 29928323; PMCID: PMC6004646.
Copy Download .nbib Format: NLM
The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review).

Oncology reports

Stachyra-Strawa P, Ciesielka M, Janiszewski M, Grzybowska-Szatkowska L.
PMID: 34109986
Oncol Rep. 2021 Aug;46(2). doi: 10.3892/or.2021.8109. Epub 2021 Jun 10.

Skin melanomas are malignant neoplasms originating from neuroectodermal melanocytes. Compared to other neoplasms, melanomas have a high rate of growth. Their incidence is highest in Australia and New Zealand, in high‑income European countries (Switzerland, Norway, Sweden) and in the...

Cite
Stachyra-Strawa P, Ciesielka M, Janiszewski M, et al. The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). Oncol Rep. 2021;46(2)doi: 10.3892/or.2021.8109.
Stachyra-Strawa, P., Ciesielka, M., Janiszewski, M., & Grzybowska-Szatkowska, L. (2021). The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). Oncology reports, 46(2), . https://doi.org/10.3892/or.2021.8109
Stachyra-Strawa, Paulina, et al. "The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review)." Oncology reports vol. 46,2 (2021). doi: https://doi.org/10.3892/or.2021.8109
Stachyra-Strawa P, Ciesielka M, Janiszewski M, Grzybowska-Szatkowska L. The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). Oncol Rep. 2021 Aug;46(2). doi: 10.3892/or.2021.8109. Epub 2021 Jun 10. PMID: 34109986.
Copy Download .nbib Format: NLM
Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review.

Case reports in oncological medicine

Bilski M, Surdyka D, Paśnik I, Bilska M, Cisek P, Korona P, Szumiło J, Grzybowska-Szatkowska L.
PMID: 29607237
Case Rep Oncol Med. 2018 Feb 11;2018:8672407. doi: 10.1155/2018/8672407. eCollection 2018.

Spleen sarcoma is one of the most rare soft tissue malignancies. The annual incidence is 0.14-0.25/1,000,000 and the average age of diagnosis is 50 to 73 years. The incidence of this cancer has been increasing. Treatment of choice is...

Cite
Bilski M, Surdyka D, Paśnik I, et al. Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review. Case Rep Oncol Med. 2018;2018:8672407doi: 10.1155/2018/8672407.
Bilski, M., Surdyka, D., Paśnik, I., Bilska, M., Cisek, P., Korona, P., Szumiło, J., & Grzybowska-Szatkowska, L. (2018). Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review. Case reports in oncological medicine, 20188672407. https://doi.org/10.1155/2018/8672407
Bilski, M, et al. "Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review." Case reports in oncological medicine vol. 2018 (2018): 8672407. doi: https://doi.org/10.1155/2018/8672407
Bilski M, Surdyka D, Paśnik I, Bilska M, Cisek P, Korona P, Szumiło J, Grzybowska-Szatkowska L. Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review. Case Rep Oncol Med. 2018 Feb 11;2018:8672407. doi: 10.1155/2018/8672407. eCollection 2018. PMID: 29607237; PMCID: PMC5828302.
Copy Download .nbib Format: NLM
Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye.

Cancers

Cisek P, Kieszko D, Bilski M, Dębicki R, Grywalska E, Hrynkiewicz R, Bębnowska D, Kordzińska-Cisek I, Rolińska A, Niedźwiedzka-Rystwej P, Grzybowska-Szatkowska L.
PMID: 33804710
Cancers (Basel). 2021 Mar 20;13(6). doi: 10.3390/cancers13061425.

BACKGROUND: Eyelid tumors are rare skin cancers, the most common of which is basal cell carcinoma characterized primarily by local growth. In addition to surgery, radiotherapy is among the basic methods of treatment. External beam radiotherapy is associated with...

Cite
Cisek P, Kieszko D, Bilski M, et al. Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061425.
Cisek, P., Kieszko, D., Bilski, M., Dębicki, R., Grywalska, E., Hrynkiewicz, R., Bębnowska, D., Kordzińska-Cisek, I., Rolińska, A., Niedźwiedzka-Rystwej, P., & Grzybowska-Szatkowska, L. (2021). Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye. Cancers, 13(6), . https://doi.org/10.3390/cancers13061425
Cisek, Paweł, et al. "Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061425
Cisek P, Kieszko D, Bilski M, Dębicki R, Grywalska E, Hrynkiewicz R, Bębnowska D, Kordzińska-Cisek I, Rolińska A, Niedźwiedzka-Rystwej P, Grzybowska-Szatkowska L. Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye. Cancers (Basel). 2021 Mar 20;13(6). doi: 10.3390/cancers13061425. PMID: 33804710; PMCID: PMC8003955.
Copy Download .nbib Format: NLM
The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience.

Cancer management and research

Kordzińska-Cisek I, Cisek P, Grzybowska-Szatkowska L.
PMID: 32104086
Cancer Manag Res. 2020 Feb 11;12:1047-1067. doi: 10.2147/CMAR.S233431. eCollection 2020.

PURPOSE: Salivary gland neoplasms are rare cancers of the head and neck region. Radical treatment in tumors of large salivary glands is surgery. Adjuvant treatment depends on the presence of risk factors that worsen the prognosis, but the role...

Cite
Kordzińska-Cisek I, Cisek P, Grzybowska-Szatkowska L. The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience. Cancer Manag Res. 2020;12:1047-1067doi: 10.2147/CMAR.S233431.
Kordzińska-Cisek, I., Cisek, P., & Grzybowska-Szatkowska, L. (2020). The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience. Cancer management and research, 121047-1067. https://doi.org/10.2147/CMAR.S233431
Kordzińska-Cisek, Izabela, et al. "The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience." Cancer management and research vol. 12 (2020): 1047-1067. doi: https://doi.org/10.2147/CMAR.S233431
Kordzińska-Cisek I, Cisek P, Grzybowska-Szatkowska L. The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience. Cancer Manag Res. 2020 Feb 11;12:1047-1067. doi: 10.2147/CMAR.S233431. eCollection 2020. PMID: 32104086; PMCID: PMC7023861.
Copy Download .nbib Format: NLM
Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Oncology letters

Kozakiewicz P, Grzybowska-Szatkowska L.
PMID: 29725456
Oncol Lett. 2018 May;15(5):7497-7505. doi: 10.3892/ol.2018.8300. Epub 2018 Mar 20.

Despite the development of standard therapies, including surgery, radiotherapy and chemotherapy, survival rates for head and neck squamous cell carcinoma (HNSCC) have not changed significantly over the past three decades. Complete recovery is achieved in

Cite
Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol Lett. 2018;15(5):7497-7505doi: 10.3892/ol.2018.8300.
Kozakiewicz, P., & Grzybowska-Szatkowska, L. (2018). Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncology letters, 15(5), 7497-7505. https://doi.org/10.3892/ol.2018.8300
Kozakiewicz, Paulina, and Grzybowska-Szatkowska, Ludmiła. "Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma." Oncology letters vol. 15,5 (2018): 7497-7505. doi: https://doi.org/10.3892/ol.2018.8300
Kozakiewicz P, Grzybowska-Szatkowska L. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. Oncol Lett. 2018 May;15(5):7497-7505. doi: 10.3892/ol.2018.8300. Epub 2018 Mar 20. PMID: 29725456; PMCID: PMC5920345.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries